Ppar-gamma agonist as target for the treatment of rapidly progressive glomerulonephritis

This study demonstrates the pivotal role of the local PPAR-gamma agonist system in maintaining podocyte quiescence and orchestrating the global glomerular tolerance to a severe immune-complex-mediated disease. PPAR-gamma agonist was found to be a downstream effector of the NRF2 pathway, unveiling the critical protective role of both NRF2 activity and PPAR-gamma. We also provide proof of principle that delayed PPAR-gamma agonism could display therapeutic action on glomerular function and structure in a severe model of Rapidly Progressive GlomeruloNephritis. (J Am Soc Nephrol. 2016 Jan;27(1):172-88. doi: 10.1681/ASN.2014111080. Epub 2015 May 21.)

Keywords: Rapidly Progressive GlomeruloNephritis
Patent Application number: PCT/FR2014/052802
Inventors:
Carole HENIQUE-GRECIETPierre-Louis THARAUXGuillaume BOLLÉE
Publications:
J Am Soc Nephrol. 2016 Jan;27(1):172-88. doi: 10.1681/ASN.2014111080. Epub 2015 May 21.

Reference:

BIO13363-T1

Business Developper
contact
Aymeric Empereur
Aymeric Empereur
Business Developer
Patent filling date: 2014-11-04
Rare disease: Yes
Second indication: Yes

You might also be interested in

Contact

Inserm Transfert

Research tool licensing team

researchtools@inserm-transfert.fr